Cerliponase Alfa Dosage
Medically reviewed by drugclasses.com. Last updated on May 27, 2024.
Applies to the following strengths: 150 mg/5 mL
Usual Pediatric Dose for:
Additional dosage information:
Usual Pediatric Dose for Neuronal Ceroid Lipofuscinosis
3 years or older: 300 mg by intraventricular infusion once every other week
Comments:
- Pretreatment with antihistamines with or without antipyretics or corticosteroids should occur 30 to 60 minutes prior to the start of infusion.
- Prior to each infusion, inspect the scalp for signs of intraventricular access device leakage, failure, or potential infection.
- Prior to each infusion, and when clinically indicated, obtain a sample of CSF for cell count and culture.
- Infusion rate 2.5 mL/hr; administer with the B Braun Perfusor Space Infusion Pump System, follow infusion with Intraventricular Electrolytes provided in the administration kit.
Use: To slow the loss of ambulation in symptomatic pediatric patients 3 years or older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Any sign or symptom of acute, unresolved localized infection on or around the device insertion site (e.g. cellulitis or abscess); or suspected or confirmed CNS infection (e.g. cloudy CSF or positive CSF gram stain, or meningitis)
- Any acute intraventricular access device-related complication (e.g., leakage, extravasation of fluid, or device failure)
- Ventriculoperitoneal shunts
Safety and efficacy have not been established in patients younger than 3 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Administered into CSF by intraventricular infusion via a surgically implanted reservoir and catheter (intraventricular access device).
- Must only be administered by the intraventricular route, using the provided administration kit; each vial of this drug and electrolytes is for single use only.
- Each infusion consists of 10 mL of this drug followed by 2 mL of intraventricular electrolytes; administer using an infusion set with a 0.2 micron inline filter.
- Infuse both this drug and electrolytes at an infusion rate of 2.5 mL/hr; complete infusion, including required electrolytes, is about 4.5 hours.
- The Codman HOLTER RICKHAM Reservoirs should be used with the Codman Ventricular Catheter.
- To be administered with the B Braun Perfusor Space Infusion System; consult the manufacturer product information for additional information.
- The intraventricular access device must be implanted prior to the first infusion and the first dose administered at least 5 to 7 days after device implantation.
- Aseptic technique must be strictly enforced during preparation and administration.
- To be administered by, or under the direction of a physician knowledgeable in intraventricular administration.
- The manufacturer product information should be consulted for direction in the intraventricular infusion procedure.
Storage requirements:
- Store drug vials and intraventricular electrolyte injection vials upright in original carton in a freezer (-25C to -15C); protect from light
- Store administration kit separately from drug vials and intraventricular electrolytes; do not freeze
- Thawed Product: Use thawed drug and Intraventricular Electrolytes immediately; if not used immediately, store
- Product in Syringes: Use product held in labeled syringes immediately; if not used immediately, store product held in labeled
Reconstitution/preparation techniques:
- The manufacturer product information should be consulted.
Monitoring:
- Cardiovascular: Monitor vital signs (e.g., blood pressure, heart rate) prior to infusion, periodically during infusion, and post-infusion in a healthcare setting; perform ECG monitoring during infusion in patients with a history of bradycardia, conduction disorder, or with structural heart disease; perform regular 12-lead ECG evaluations every 6 months in patients without cardiac abnormalities
- Hypersensitivity: Observe patients closely during and after infusion for signs/symptoms of allergic reactions, including anaphylaxis
- Nervous System: Prior to each infusion, inspect the scalp for signs of intraventricular access device leakage, failure, or potential infection; prior to each infusion, and when clinically indicated, obtain a sample of CSF for cell count and culture
Patient advice:
- Advise patients/caregivers to immediately contact their healthcare provider if any signs of infection occur.
- Advise patients/caregivers to immediately contact their healthcare provider if hypotension and/or bradycardia occur during or following infusion.
- Advise patients/caregivers to seek medical attention if any signs/symptoms of a hypersensitivity reaction (e.g., fever, vomiting, irritability) or signs/symptoms of anaphylaxis occur.
Frequently asked questions
More about cerliponase alfa
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.